Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary adenosine before stenting during primary PCI for STEMI no-reflow prevention
IRCT20120516009768N6Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of adenosine in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Occurrence of no-reflow phenomenon. Started Mar 2019; status: completed.
02
Drugs
adenosine
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT20120516009768N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120516009768N6.